Summary
Investigate the inhibitor development rate of Human cl rhFVIII in previously untreated patients with severe Hemophilia A.
Conditions
Severe Hemophilia A
Recruitment Status
COMPLETED
Eligibility Criteria
Inclusion Criteria:
* Male patients
* Severe Hemophilia A (FVIII:C \<1%)
* No previous treatment with FVIII concentrates or other blood products containing FVIII
Exclusion Criteria:
* Diagnosis with a coagulation disorder other than Hemophilia A
* Severe liver or kidney disease
* Concomitant treatment with any systemic immunosuppressive drug
Intervention
Intervention Type
Intervention Name
BIOLOGICAL
Human cl rhFVIII
Phase
PHASE3
Gender
MALE
Min Age
N/A
Max Age
N/A
Download Date
2021-01-19
Principal Investigator
N/A
Primary Contact Information
For more information on this trial, visit clinicaltrials.gov.
Contact
For more information and to contact the study team:
Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients
NCT01712438